Trending
Prev Story
Next Story

Judge approves $7.25bn Bayer settlement for Roundup cancer claims

BBC News •
November 21, 2026 • 03:49 AM
2
2 reads 0 reactions

The settlement will be paid by Bayer to users who already have non-Hodgkin lymphoma and those who fall ill in the future.

1 / 2
Swipe Photos

A Missouri judge on Friday approved a $7.25bn (£5.5bn) settlement stemming from lawsuits ⁠alleging that Bayer's weedkiller Roundup causes cancer.

Judge Timothy Boyer said the settlement was "fair, reasonable, and adequate".

Bayer, the German bio-tech giant, had proposed paying the $7.25bn to definitively resolve a legal battle in the US.

The nationwide settlement will be paid to Roundup users who are already sick with non-Hodgkin lymphoma and those who fall ill in the future.

The company had already paid roughly $10bn to resolve litigation related to Roundup.

The settlements to participants range from $10,000 to $165,000, depending on how frequently they used the product, when they were diagnosed with the cancer and how severe their illness was.

Bayer will make annual payments into a fund for up to 21 years, providing as much as $7.25bn.

Some attorneys had objected to the settlement funds, arguing they were not enough, but the judge said he did not want to delay payouts to sick victims.

Bayer denies that its Roundup product causes cancer.

The settlement comes after the Supreme Court in June ruled in favour of Bayer, overturning a $1.25m settlement for a Missouri man who said Roundup and its ingredient glyphosate was to blame for his non-Hodgkin lymphoma.

The court ruled 7-2, saying Bayer cannot be sued in state courts because federal regulations do not mandate a cancer warning label.

The company has faced thousands of claims in US state and federal courts from people alleging they developed cancer after using the product.

Roundup was developed by Monsanto in the 1970s. Its active ingredient, glyphosate, was identified by the International Agency for Research on Cancer, a unit of the World Health Organization in 2015 as a probable human carcinogen.

Bayer and some other regulators, including the US Environmental Protection Agency, have disputed those findings.

But the issue has forced the company through years of costly litigation in the US, as juries in several states opt to award billions of dollars to users of the herbicide.

Prev Swipe Story Next

Same Story from Other Publications

Compare how 6 other independent news outlets reported on this story.

6 Publications
The Guardian
5h ago
Judge approves $7.25bn Bayer payout to settle claims that Roundup causes cancer

Judge approves $7.25bn Bayer payout to settle claims that Roundup causes cancer

German company faced 65,000 claims from people who said they developed cancer after using weedkiller

#bayer #roundup #cancer
Compare →
ABC News Australia
2h ago
Bayer to pay $11b over claims weed killer caused cancer

Bayer to pay $11b over claims weed killer caused cancer

The US settlement handed down in Missouri applies to Roundup weed-killer users who are ill and those who become diagnosed with non-Hodgkin lymphoma in future years.

#bayer #roundup #cancer
Compare →
CNN International
17h ago
Lung cancer screening recommended for 40s | CNN

Lung cancer screening recommended for 40s | CNN

Lung cancer, the leading cause of cancer deaths in the US, often goes undetected until it’s too late under current screening guidelines. CNN’s Meg Tirrell visits Northwestern Medicine in Chicago to speak to a doctor pushing for earlier, broader lung cancer screening.

The Age
1d ago
Bassist of Brisbane band Bugs dies after year-long fight with cancer

Bassist of Brisbane band Bugs dies after year-long fight with cancer

Jordan Brunoli, 31, formed one-third of the indie-rock band, which released its fourth album months before his death.

Ars Technica
1w ago
In reversal, American Cancer Society urges prostate cancer tests for all men

In reversal, American Cancer Society urges prostate cancer tests for all men

Men aged 50–69 and at average risk should get PSA screening every two years.

The Next Web (TNW)
1w ago
Orakl Oncology raises $34M to predict cancer drug results with AI

Orakl Oncology raises $34M to predict cancer drug results with AI

Paris-based Orakl Oncology has raised a $34M Series A to predict how cancer drugs will perform, using lab-grown copies of patients' tumours and AI.

Related Stories

Technology
Build #2612